Kymera Therapeutics Accelerates KT-621 Atopic Dermatitis Trial Enrollment, Bringing Topline Data Forward by Six Months
KYMR has more than doubled off its 52-week low of $36.65 on elevated volume (2.0× avg).
Summary
Kymera Therapeutics announced the early completion of enrollment for its Phase 2b trial of KT-621 in atopic dermatitis, accelerating the topline data readout to year-end 2026.
Key Events · Product Development and Regulatory · KYMR
-
Phase 2b Enrollment Completed Early
Kymera Therapeutics has completed enrollment in its global BROADEN2 Phase 2b trial for KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis, ahead of prior expectations.
-
Topline Data Accelerated by Six Months
The early completion of enrollment accelerates the anticipated topline data readout for the BROADEN2 trial to year-end 2026, moving it forward by approximately six months from the previous mid-2027 guidance.
-
Phase 3 Trials Planned for Mid-2027
Subject to discussions with regulators, the company expects to initiate Phase 3 trials for KT-621 in atopic dermatitis by mid-2027.
Analysis · KYMR · Life Sciences
Kymera Therapeutics has completed enrollment for its pivotal Phase 2b BROADEN2 trial of KT-621 for atopic dermatitis significantly ahead of schedule. This accelerates the anticipated topline data readout by six months to year-end 2026, a critical de-risking event for this lead immunology program. Earlier data could expedite the path to Phase 3 trials and potential market entry, which is highly impactful for a clinical-stage biotechnology company.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 1008 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYMR was trading at $102.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2B. The 52-week trading range was $36.65 to $105.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.